Functional UDP-glucuronyltransferase 2B15 polymorphism and bisphenol A concentrations in blood: Results from physiologically based kinetic modelling

Archives of Toxicology

Volumn 87, Issue 7, 2013, Pages 1257-1264

  Partosch, Falko ^a   Mielke, Hans ^b   Gundert Remy, Ursula ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

Bisphenol A; Internal exposure; Physiologically based kinetic modelling; Polymorphically expressed UGT2B15 metabolism; Risk assessment; Systemic availability

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; GLUCURONOSYLTRANSFERASE; PROTEIN VARIANT; RECOMBINANT ENZYME; SULFATE; UDP GLUCURONYLTRANSFERASE 2B15; UNCLASSIFIED DRUG;

4,4' ISOPROPYLIDENEDIPHENOL BLOOD LEVEL; 4,4' ISOPROPYLIDENEDIPHENOL URINE LEVEL; ARTICLE; BLOOD LEVEL; CHEMICAL MODEL; CHEMICAL PARAMETERS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME POLYMORPHISM; METABOLIC CLEARANCE RATE; METABOLISM; PRIORITY JOURNAL; TOXICOKINETICS; URINE LEVEL;

AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; ENDOCRINE DISRUPTORS; GENOTYPE; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACOGENETICS; PHENOLS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 84879151120     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-013-1022-8     Document Type: Article

References (44)

1. Abraham K, Mielke H, Huisinga W, Gundert-Remy U (2005) Elevated internal exposure of children in simulated acute inhalation of volatile organic compounds: effects of concentration and duration. Arch Toxicol 79:63-73
2. Arniche N, Canivenc-Lavier M, Kolf-Clauw M, Coffigny H, Cravedi JP, Grob K, Macherey AC, Masset D, Maximilien R, Narbonne JF, Nesslany F, Stadler J, Tulliez J (2011) Conclusions of the French food safety agency on the toxicity of bisphenol A. Int J Hyg Environ Health 214:271-275
3. Biedermann S, Tschudin P, Grob K (2010) Transfer of bisphenol A from thermal printer paper to the skin. Anal Bioanal Chem 398:571-576
4. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG (2005) Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther 77:486-494
5. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116
6. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ (2004) UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310:656-665
7. Csanády GA, Oberste-Frielinghaus HR, Semder B, Baur C, Schneider KT, Filser JG (2002) Distribution and unspecific protein binding of the xenoestrogens bisphenol A and daidzein. Arch Toxicol 76:299-305
8. Dekant W, Völkel W (2008) Human exposure to bisphenol A by biomonitoring: methods, results and assessment of environmental exposures. Toxicol Appl Pharmacol 228:114-134
9. Edginton AN, Ritter L (2009) Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic model. Environ Health Perspect 117(4):645-652
10. European Food Safety Authority (2011) Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to 2,2-bis(4-hydroxyphenyl)propane. EFSA J 2011(9):2475
11. European Food Safety Authority (EFSA) (2006) Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food (AFC) related to 2,2-bis(4-hydroxyphenyl)propane; Question number EFSA-Q-2005-100, pp. 1-75. Available at http://www.efsa.europa.eu/EFSA/efsa- locale-1178620753812-1178620772817.htm. Accessed 10 Oct 2012
12. European Union (EU) (2008) Updated European risk assessment report: 4,4- isopropylidenediphenol (bisphenol-A) (CAS number: 80-05-7, EINECS number: 201-245-8). Available at http://publications.jrc.ec.europa.eu/repository/ bitstream/111111111/15069/1/lbna24589enn.pdf. Accessed 12 Jan 2013
13. FAO/WHO (2011) Toxicological and health aspects of bisphenol A. Report of joint FAO/WHO expert meeting. World Health Organization. ISBN 978 92 141 56427 4
14. Fisher JW, Twaddle NC, Vanlandingham M, Doerge DR (2011) Pharmacokinetic modeling: prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicol Appl Pharmacol 257:122-136
15. Fukata H, Miyagawa H, Yamazaki N, Mori C (2006) Comparison of ELISA- and LCMS-based methodologies for the exposure assessment of bisphenol A. Toxicol Mech Methods 16:427-430
16. Geens T, Aerts D, Berthot C, Bourguignon JP, Goeyens L, Lecomte P, Maghuin-Rogister G, Pironnet AM, Pussemier L, Scippo ML, Van Loco J, Covaci A (2012) A review of dietary and non-dietary exposure to bisphenol-A. Food Chem Toxicol 50:3725-3740
17. Hanioka N, Naito T, Narimatsu S (2008) Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 24:33-36
18. Hanioka N, Oka H, Nagaoka K, Ikushiro S, Narimatsu S (2011) Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch Toxicol 85:1373-1381
19. He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, Court MH (2009) Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol 68:721-730
20. Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth H, Völkel W, Wollin KM, Gundert-Remy U (2011) Cutting edge topics of the current controversy on BPA. Crit Rev Toxicol 41:263-291
21. Ikezuki Y, Tsutsumi O, Takai Y, Kamei Y, Taketani Y (2002) Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod 17:2839-2841
22. IPCS (2005) Chemical-specifc adjustment factors for Interspecies differences and human variability: Guidance document for use of data in dose/concentration-response assessment. World Health Organization, Geneva
23. Kuester RK, Sipes IG (2007) Prediction of metabolic clearance of bisphenol A (4,4-dihydroxy-2,2-diphenylpropane) using cryopreserved human hepatocytes. Drug Metab Dispos 35:1910-1915
24. Kurebayashi H, Okudaira K, Ohno Y (2010) Species difference of metabolic clearance of bisphenol A using cryopreserved hepatocytes from rats, monkeys and humans. Toxicol Lett 198:210-215
25. Lakind JS, Naiman DQ (2011) Daily intake of bisphenol A and potential sources of exposure: 2005-2006. National health and nutrition examination survey. J Expo Sci Environ Epidemiol 21:272-279
26. Lee YJ, Ryu HY, Kim HK, Min CS, Lee JH, Kim E, Nam BH, Park JH, Jung JY, Jang DD, Park EY, Lee KH, Ma JY, Won HS, Im MW, Leem JH, Hong YC, Yoon HS (2008) Maternal and fetal exposure to bisphenol A in Korea. Reprod Toxicol 25:413-419
27. Markham DA, Waechter JM Jr, Wimber M, Rao N, Connolly P, Chuang JC, Hentges S, Shiotsuka RN, Dimond S, Chappelle AH (2010) Development of a method for the determination of bisphenol A at trace concentrations in human blood and urine and elucidation of factors influencing method accuracy and sensitivity. J Anal Toxicol 34:293-303
28. Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC (2010) Differences between human and rat intestinal and hepatic bisphenol-A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos 38:2232-2238
29. Mielke H, Gundert-Remy U (2009) Bisphenol A levels in blood depend on age and exposure. Toxicol Lett 190:32-40
30. Mielke H, Gundert-Remy U (2012) Physiologically based toxicokinetic modelling as a tool to support risk assessment: three case studies. J Toxicol 2012:359471
31. Mielke H, Partosch F, Gundert-Remy U (2011) The contribution of dermal exposure to the internal exposure of bisphenol A in man. Toxicol Lett 204:190-198
32. Padmanabhan V, Siefert K, Ransom S, Johnson T, Pinkerton J, Anderson L, Tao L, Kannan K (2008) Maternal bisphenol-A levels at delivery: a looming problem? J Perinatol 28:258-263
33. Sajiki J, Takahashi K, Yonekubo J (1999) Sensitive method for the determination of bisphenol-A in serum using two systems of high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 736:255-261
34. Schmitt W (2008) General approach for the calculation of tissue to plasma partition coefficient. Toxicol In Vitro 22:457-467
35. Schönfelder G, Wittfoht W, Hopp H, Talsness CE, Paul M, Chahoud I (2002) Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Perspect 110:A703-A707
36. Takeuchi T, Tsutsumi O (2002) Serum bisphenol a concentrations showed gender differences, possibly linked to androgen levels. Biochem Biophys Res Commun 291:76-78
37. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y (2004) Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 51:165-169
38. Teeguarden JG, Calafat AM, Ye X, Doerge DR, Churchwell MI, Gunawan R, Graham MK (2011) Twenty-four hour human urine and serum profiles of bisphenol a during high-dietary exposure. Toxicol Sci 123:48-57
39. Tsukioka T, Terasawa J, Sato S, Hatayama Y, Makino T, Nakazawa H (2004) Development of analytical method for determining trace amounts of BPA in urine samples and estimation of exposure to BPA. J Environ Chem 14:57-63
40. Vandentorren S, Zeman F, Morin L, Sarter H, Bidondo ML, Oleko A, Leridon H (2011) Bisphenol-A and phthalates contamination of urine samples by catheters in the Elfe pilot study: implications for large-scale biomonitoring studies. Environ Res 111:761-764
41. Völkel W, Bittner N, Dekant W (2005) Quantitation of bisphenol A and bisphenol A glucuronide in biological samples by high performance liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 33:1748-57
42. Völkel W, Colnot T, Csanady GA, Filser JG, Dekant W (2002) Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol 15:1281-1287
43. Völkel W, Kiranoglu M, Fromme H (2008) Determination of free and total bisphenol A in human urine to assess daily uptake as a basis for a valid risk assessment. Toxicol Lett 179:155-162
44. Yamada H, Furuta I, Kato EH, Kataoka S, Usuki Y, Kobashi G, Sata F, Kishi R, Fujimoto S (2002) Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. Reprod Toxicol 16:735-739